A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.

See if you qualify! Learn more

Brief Summary:

The main objective of the trial is to demonstrate a dose-relationship of BI 456906 on Glycosylated hemoglobin A1c (HbA1c)(absolute change) from baseline to 16 weeks relative to placebo in patients with Type 2 diabetes mellitus (T2DM).

Secondary objectives are to assess the effect of BI 456906 on change in body weight. An open-label comparator (semaglutide) will allow for comparison of the effects against a pure Glucagon-like-peptide 1 receptor (GLP-1R) agonist.

For more information, please visit www.clinicaltrials.gov.

Benefits


Receive free medications and free supplies!

Gain better understanding of your disease and take an active role in your health.

Obtain treatments not yet available and contribute to medical research.

Travel stipends for attending most scheduled research appointments.

On average patients receives free care worth $250 - $500 from diabetes experts.

So far Iowa Diabetes Research has spent more than $500K on patients benefits

Meet Your Research Team

Anuj Bhargava

Anuj Bhargava

CEO and Medical Director

Kathy Fitzgerald

Kathy Fitzgerald

Sub-Investigator

Tara Herrold

Tara Herrold

CRC Manager

Lisa Borg

Lisa Borg

Clinical Research Coordinator

Natalie Young

Natalie Young

Clinical Research Coordinator

Kirstie Stifel

Kirstie Stifel

Clinical Research Coordinator

Kendra Kramer

Kendra Kramer

Clinical Research Coordinator

Kara Turner

Kara Turner

Clinical Research Coordinator

Questions?